The Addario Lung Cancer Medical Institute (ALCMI) team includes distinguished physicians, leading scientists and clinicians, innovative business executives, thought leaders and lung cancer survivors and their families all dedicated to our ambitious mission to help turn lung cancer into a chronically-managed disease by 2023.
Richard recently served as Vice President Clinical Operations for Tetra Discovery Partners, and as Executive Director of Clinical Operations and Project Management for Catalyst Pharmaceuticals. Richard additionally oversaw the global phase 3 development program of VaxChora™, a single dose cholera vaccine developed by Silicon Valley’s PaxVax, which received FDA approval under Priority Review in June of 2016. Other past experience includes product development team leadership for global Phase 3 CNS and oncology programs at Neurocrine Biosciences; a clinical innovation joint venture with Eli Lilly & Co and Quintiles; work across Africa enhancing clinical capacity infrastructure; and clinical operations leadership at early biotech startups including Cytheris, British Biotech, and Amgen – where he was a Clinical Research Associate (CRA) for the oncology blockbuster, Neupogen™. Mr. Erwin earned a Bachelor of Science degree in Microbiology from the University of Michigan, Ann Arbor.
Scientific Leadership Board
ALCMI’s Scientific Leadership Board (SLB) is the research consortium’s executive scientific committee and is comprised of a number of the world’s leading lung cancer researchers. The SLB sets the organization’s scientific agenda, research priorities and develops/reviews the consortium’s collaborative research projects.
After an Internal Medicine internship and residency at The Johns Hopkins Hospital he did a Medical Oncology fellowship at the National Cancer Institute in Bethesda, MD. At Vanderbilt he was Director of the Thoracic/Head and Neck Cancer Program, Director of a SPORE in Lung Cancer for 11 years. He was recruited to the Ohio State University in 2012 to direct the James Thoracic Center.
His research interests have been focused on lung cancer, and specifically proteomic and expression signature development, lung cancer genetics, tumor-associated immunosuppression mechanisms, proteogenomic profiling of lung cancers to guide the development of novel therapeutics, and targeting novel immunosuppression mechanisms. He has over 200 peer-reviewed publications, has served on the Board of Scientific Counselors, and has continuous NCI funding since early in his career. He is currently Chair of the Lung Biology subcommittee for the Eastern Cooperative Oncology Group and President of the International Association for the Study of Lung Cancer (IASLC).
Dr. Gandara received his medical degree from the University of Texas Medical Branch in Galveston, followed by internship and residency at the Madigan Army Medical Center in Tacoma and a fellowship at the Letterman Army Medical Center Presidio of San Francisco.
Dr. Gandara is a diplomat of the American Board of Internal Medicine specializing in Medical Oncology. He is currently principal investigator for a number of research projects in lung cancer, pharmacology trials at various phases, and Southwest Oncology Group trials. He is the principal investigator for a National Cancer Institute award to the California Cancer Consortium for Early Therapeutic Trials of New Anti-Cancer Agents.
Dr. Gandara is President of the International Association for the Study of Lung Cancer (IASLC) and serves on the board of directors. Dr. Gandara is chair of the Southwest Oncology Group (SWOG) Lung Committee, and co-chair of the NCI-directed Investigational Drug Steering Committee. He has written over 300 articles, book chapters, abstracts and editorials. He is editor-in-chief of Clinical Lung Cancer, serves on the editorial board of four oncology journals, and is a manuscript reviewer for eight additional journals. He served as secretary-treasurer and a member of the board of directors for the American Society of Clinical Oncology (ASCO). Dr. Gandara is a member of the Scientific Leadership Council in Lung Cancer.
Dr. Jablons received his undergraduate degree from Yale University and his medical degree from Albany Medical College of Union University. He has also trained at numerous highly-regarded institutions including Tufts-New England Medical Center, Oak Knoll Naval Hospital, the Surgery Branch of NCI, Cornell University Medical Center, New York Hospital/Memorial Sloan Kettering Cancer Center, and Brigham & Women’s Hospital.
Dr. Jablons established the UCSF/UC Davis Thoracic Oncology Conference, one of the oldest and longest running didactic conferences in the field. He also helped found the International Pan Pacific Lung Cancer Conference. He is a strong supporter of international efforts to expand lung cancer research, and helped start the China Clinical Trials Consortium (CCTC). He also co-founded the Bonnie J. Addario Lung Cancer Foundation and the Addario Lung Cancer Medical Institute.
Dr. Jablons leads a team of scientists developing molecularly targeted therapies for lung cancer and mesothelioma. Key research areas include the Wnt and Hedgehog (Hh) pathways, and stem cell signaling targets. The Thoracic Oncology Tissue Bank is one of the largest such repositories in the U.S. and serves as a hub for interdisciplinary collaboration. Dr. Jablons is also a principal investigator on two NIH R01 grants and has authored over 100 peer-reviewed research papers. In addition, he serves as a reviewer on several NIH study groups.
After earning his MD and PhD from the School of Medicine at the University of Pennsylvania, Dr Jänne completed his internship and residency in Medicine at Brigham and Women’s Hospital, Boston. He subsequently completed fellowship training at Dana Farber Cancer Institute/Massachusetts General Hospital combined program in medical oncology in 2001. In 2002 he earned a Masters Degree in clinical investigation from Harvard University.
Dr. Jänne’s research interests include investigation of oncogene mutations and how these correlate with clinical response to targeted therapies in lung cancer. He was one of the investigators who initially discovered EGFR mutations in 2004 and has subsequently studied their effect on clinical outcome of patients and on mechanisms of resistance. He has also worked on developing non-sequencing based technology to detect mutations in EGFR and other oncogenes. Dr. Jänne is a member of the Cancer and Leukemia Group B respiratory committee. He is also an active member of ASCO, AACR, ESMO and IASLC. He was elected to the American Society of Clinical Investigation in 2008.
Dr. Laird-Offringa earned her Ph.D. from the University of Leiden, The Netherlands, and conducted postdoctoral work at Harvard Medical School. She joined the USC faculty in 1996. She is a member of many national and international professional and advocate societies, including the American Association for Cancer Research, the International Association for the Study of Lung Cancer, and the National Lung Cancer Partnership, and she serves as a reviewer on the NIH/NCI Cancer Genetics study section.
Dr. Laird-Offringa is committed to the development of better tools for early lung cancer detection. Her laboratory’s current research in lung cancer focuses on the identification of cancer-specific changes in antibodies and in DNA methylation, a reversible alteration of DNA that can affect gene expression. The obtained information is used for biomarker development and to gain insight into the sequential molecular steps that happen during the development of lung cancer. The Laird-Offringa laboratory is funded by two NIH R01 grants and by generous donations and grants from several private foundations and individuals. In her work, she collaborates with pathologists, oncologists, surgeons, epidemiologists and a variety of other scientists.
Dr. Pass received his B.A. from Johns Hopkins University and his M.D. from Duke University. He completed his surgical residency at Duke and University of Mississippi. He completed his residency in Cardiothoracic Surgery at the Medical University of South Carolina. Dr. Pass also completed a fellowship in Thoracic Oncology at NCI.
Dr. Pass has published over 300 manuscripts in peer-reviewed journals, including The New England Journal of Medicine regarding the discovery of osteopontin as a possible early detection biomarker for mesothelioma. He is an editor of Lung Cancer: Principles and Practice, Surgery: Basic Science and Clinical Evidence, Oncology: An Evidence Based Approach, and Malignant Mesothelioma: Advances in Pathogenesis, Diagnosis, and Translational Therapies. Dr. Pass is Associate Editor for the Journal of Thoracic Oncology, Surgical Editor for Clinical Lung Cancer and a member of the editorial board for Clinical Cancer Research.
Dr. Pass is presently on the Board of Directors for the International Association for the Study of Lung Cancer, the International Mesothelioma Interest Group, the Lung Cancer Alliance, and the Mesothelioma Foundation.
Dr. Rosell is the founder and President of the Spanish Lung Cancer Group (SLCG), Chairman of the IASLC 2005 World Conference on Lung Cancer, and Co-Chair of the 1st and 2nd IASLC-ESMO European Lung Cancer Conferences. He is an active member of the ESMO Educational Committee, and the EORTC Protocol Review Committee. He is on the Editorial Board of several peer-reviewed medical journals. Dr. Rosell has authored over 450 articles in peer-reviewed journals and given more than 600 presentations at conferences around the world.
Since the early 1990s, Dr. Rosell has been involved in the application of genetic research to the clinical setting. Recent translational research by Dr Rosell’s group has focused on chemosensitivity in relation to polymorphisms of DNA repair genes, methylation patterns in circulating DNA, and gene expression profiles in RNA. Dr. Rosell’s group is also involved in research on EGFR mutations and has implemented large-scale screening for EGFR mutations in newly-diagnosed lung cancer patients in Spain in order to select patients for treatment with EGFR inhibitors instead of chemotherapy as first-line treatment. In the SLCG’s ongoing trials in the adjuvant and the metastatic setting of NSCLC, customized chemotherapy and targeted therapy are being implemented as standard treatment.
Over the last 15 years Dr. Scagliotti’s research interests included experimental studies on basic and clinical applied research on lung cancer, including translational research. He has been and currently is the study coordinator of several European and international clinical trials on lung cancer chemotherapy and he has been a key investigator in several Italian studies investigating the role of chemotherapy in early stage non-small cell lung cancer. Dr. Scagliotti is a member of numerous scientific societies, including the Italian Society of Respiratory Medicine, the European Respiratory Society, the American Society of Clinical Oncology and the International Association for the Study of Lung Cancer. From 2002 to 2005 he was member of the International Affair Committee of the American Society of Clinical Oncology and from 2003-07 Executive Board member of the International Association for the Study of Lung Cancer. He served on the Publication Committee (2005-08) and in Program Committee of the American Society of Clinical Oncology in the period 2005-07. Dr. Scagliotti is a manuscript reviewer for 11 scientific journals. He currently serves on the editorial boards of Critical Review in Oncology and Hematology, and Oncology News. He is Associate Editor for Journal of Thoracic Oncology and International Editor for Clinical Lung Cancer. He is the author or co-author of more than 180 publications in peer-reviewed journals and he is the International Editor of the 4th Edition of the book “Lung Cancer : Principles and practice”
Board of Directors
The all-voluntary Board of Directors is responsible for ensuring the excellent management (including fiscal performance/accountability) of ALCMI, establishes and/or approves policies and procedures, and generally oversees the business and affairs of the organization.
While helping to shape the firm’s business strategy, Sam maintains close client relationships. He applies his business acumen to a host of unique client situations and enjoys the intellectual challenge of identifying and developing solutions to otherwise complicated problems. He works closely with the wealth strategies team on complex estate, tax and gift planning strategies and has served on the boards of multiple early-stage venture companies and non-profit organizations.
Sam believes that education is the cornerstone of all personal and organizational growth, and has committed himself to various institutions that promote knowledge. He translates this belief in learning to Bainco, ensuring that all client advice comes with an educative delivery that benefits the collective knowledge of his clients and employees. In 2016, Sam was the recipient of the 2016 UVM Alumni Association Distinguished Service Award for his guidance through tough financial times as the chair of the Investment Sub-Committee.
Mr. Florsheim is a prostate cancer, lung cancer and melanoma survivor. In addition to serving on the ALCMI Board, he is a patient advocate member of the Protocol Review and Monitoring Committee for UT Southwestern Simmons Comprehensive Cancer Center, a patient advocate member of the UT Southwestern SPORE in Lung Cancer, a consumer reviewer for the DOD’s Congressionally Directed Lung Cancer Research Program, the patient advocate member of the Thoracic Committee of ECOG/ACRIN Cancer Research Group, a patient advocate member of the NCI ALCHEMIST Core Committee and of the NCI MATCH Trial, and the patient advocate member of the National Comprehensive Cancer Network Small Cell Lung Cancer Panel. He is also a patient advocate member of both ASCO and IASLC.
Mr. Patel is a proven results-oriented and seasoned technology leader with 25+ years of experience developing highly scalable products and services by building and leading large, high-performance global engineering organizations, setting clear vision, directing strategy and delivering against goals. He is passionate about translating strategy to execution, and delivering the best experience for the customer.
Mr. Patel retired from Cisco in October of 2016 and now serves on the Board of Directors of several startups. He is focused on incubating, investing, and advising startups with their strategy, product development, and go-to-market as well as helping them scale. Patel is also a mentor and sponsor to numerous employees throughout the industry.
ALCMI • 1100 Industrial Road, Suite 1, San Carlos, CA 94070 • 650.598.2857 • 501c(3) Public Charity Tax ID 26-1721868
© 2019 The Addario Lung Cancer Medical Institute. All Rights Reserved.